<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Moderna Inc (NASDAQ: MRNA) shared a new follow-up analysis through 1 year in the Phase 3 COVE study, suggesting a lower risk of breakthrough infection in participants vaccinated more recently (median 8 months after the first dose) than participants vaccinated last year (median 13 months after the first dose). Related Link: Pfizer Builds Case For COVID-19 Booster As Protection Wanes Over Time
...read full article on Benzinga
